Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Neuronetics, Inc.NASDAQ: STIM

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $16.15M rose 2.6% year over year, behind the +28.0% change in trailing-twelve-month gross profit. Sequentially, it fell 25.6% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.

Context

  • Gross profit amounted to 48.5% of revenue in FY2025, down 23.8 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.6% toward the trailing-twelve-month pace of +28.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.15M-25.6% QoQ
Last fiscal yearDec 2025
$72.31M+33.5% YoY
LTMMar 2026
$72.72M+28.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.6%——
1 year+33.5%——
3-year CAGR+13.3%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
72.31M USD
Year-over-year change
+33.5%
4-year CAGR
+13.4%

Gross Profit vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.0% is the 5th highest of 10, against a peer median of -2.5%.
  • Gross profit amounts to 48.0% of revenue for STIM, versus a peer median of 58.3%.
STIM Competitors
Gross Profit for STIM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STIMNeuronetics, Inc.LTM Mar 2026$72.72M USD+28.0%+13.3%48.0%
PREPrenetics Global LimitedLTM Mar 2026$66.34M USD+249.9%+138.0%58.3%
CDXSCodexis, Inc.LTM Mar 2026$65.55M USD+83.9%-15.3%83.9%
OSUROraSure Technologies, Inc.LTM Mar 2026$46.35M USD-32.6%-31.3%41.0%
ATLNAtlantic International Corp.LTM Dec 2025$45.99M USD-2.5%-5.3%10.6%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$34.56M USD-45.8%-31.5%100.0%
PROFProfound Medical Corp.LTM Mar 2026$13.41M USD+43.6%+56.6%71.1%
OABIOmniAb, Inc.LTM Mar 2026$10.25M USD-61.7%—35.5%
NYXHNyxoah S.A.LTM Mar 2026€7.89M EUR+175.8%+48.4%48.3%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$3.03M USD-150.0%—489.8%
Peer median (excluding STIM) —-2.5%-5.3%58.3%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M65.21M71.35M74.89M149.16M
Cost of Revenue11.65M15.48M19.64M20.73M76.85M
Gross Profit43.66M49.72M51.71M54.16M72.31M
Gross Margin78.9%76.3%72.5%72.3%48.5%
Research & Development7.92M9.34M9.52M12.77M6.58M
Selling, General & Admin63.3M75.5M72.74M75.95M97.16M
Operating Expenses71.22M84.83M82.26M88.72M103.74M
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
EBITDA(26.81M)(31.96M)(22.76M)(34.37M)(27.12M)
EBITDA Margin-48.5%-49.0%-31.9%-45.9%-18.2%
Operating Income(27.56M)(35.11M)(30.55M)(34.56M)(31.44M)
Operating Margin-49.8%-53.8%-42.8%-46.2%-21.1%
Interest Income0024K00
Interest Expense3.3M3.6M5.42M7.29M8.42M
Other Income / Expenses(3.61M)(2.1M)365K(9.18M)(7.56M)
Income Before Tax(31.17M)(37.21M)(30.19M)(43.74M)(39M)
Pre-Tax Margin-56.4%-57.1%-42.3%-58.4%-26.1%
Income Tax Expense00(24K)(14K)0
Net Income(31.19M)(37.16M)(30.19M)(43.71M)(39M)
Net Margin-56.4%-57.0%-42.3%-58.4%-26.1%
EPS (Basic)(1.22)(1.38)(1.05)(1.38)(0.59)
EPS (Diluted)(1.22)(1.38)(1.05)(1.38)(0.59)
Weighted Avg Shares25.48M26.9M28.66M31.73M65.95M
Weighted Avg Shares (Diluted)25.48M26.9M28.66M31.73M65.95M

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.